Number of drugs provided by the Pharmaceutical Benefits Scheme and mortality and hospital utilization in Australia, 2002–2019
We analyze the relationship between long-run changes in the drugs provided by the Pharmaceutical Benefits Scheme (PBS) and mortality and hospital utilization in Australia, by analyzing the correlation across diseases between the change in the number of drugs used to treat the disease provided and th...
Main Author: | Frank R. Lichtenberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | SSM: Population Health |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352827323001799 |
Similar Items
-
Levodopa use in Australia: an analysis of Pharmaceutical Benefits Scheme 10% data
by: Andrew Evans, et al.
Published: (2024-01-01) -
The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013
by: Frank R. Lichtenberg
Published: (2017-10-01) -
Ins and outs of the pharmaceutical benefits scheme
by: Bennett, J, et al.
Published: (2003) -
P661: POPULATION-WIDE PATTERNS OF CARE IN CHRONIC LYMPHOCYTIC LEUKEMIA IN AUSTRALIA: AN ANALYSIS OF THE PHARMACEUTICAL BENEFITS SCHEME DATASET
by: C. Tam, et al.
Published: (2022-06-01) -
PB2082: POPULATION-WIDE PATTERNS OF CARE IN MANTLE CELL LYMPHOMA IN AUSTRALIA: AN ANALYSIS OF THE PHARMACEUTICAL BENEFITS SCHEME DATASET
by: C. Tam, et al.
Published: (2022-06-01)